AdvtBy ,ET BureauJoin the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. The probability of confusion significantly increases when prescriptions are managed by pharmacists and patients or individuals purchasing medication on their behalf, the judgement stated.The dispute arose after Intas launched its cancer drug under the name Bevatas. Sun Pharma argued that the mark was deceptively similar to its Bevetex mark and any possible confusion would pose serious public health risks.

Source: Economic Times April 01, 2026 16:36 UTC